Brazil’s Hypermarcas enjoys strong reception for buy-back

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Emerging Markets
EM LatAm

Brazil’s Hypermarcas enjoys strong reception for buy-back

Oliver West
February 29, 2016 05:00 am
Brazil, Hypermarcas, medicine, pharmacy
The national flag of Brazil on a capsule and pills on a spoon.(series) | Sebastian Gelbke/eyegelb - Fotolia

Hypermarcas, the Brazilian pharmaceutical company, will not extend the early bird deadline on the tender offer for its 6.5% senior notes due 2021 after bondholders responded positively to the buy-back offer.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

LatAm BondsEmerging MarketsBrazilLatAm
OW
Oliver West
US Bureau Chief - Latin America Editor
Contact
Gift this article